PhRMA joins NIH's HEAL Partnership Committee
The National Institutes of Health's Helping to End Addiction Long-term, or HEAL Initiative recently announced the launch of the HEAL Partnership Committee. The committee is comprised of experts in drug and device development, research and bioethics, as well as people who have experienced pain and addiction.
The Pharmaceutical Research and Manufacturers of America together with the Advanced Medical Technology Association, the Biotechnology Innovation Organization, and the Foundation for the NIH, signed a memorandum of understanding with the NIH to become a part of the HPC to communicate opportunities to advance the goals of the initiative to its member companies and identify representatives with scientific expertise who may provide knowledge and guidance.
“Opioid abuse and addiction in America is a public health crisis that we all must work together to solve. The HEAL Partnership Committee is a critical step forward in this collaboration. It provides an opportunity to share valuable data, knowledge and research across the biopharmaceutical and medical device industries, government and academia to speed the development of innovative treatments for pain and opioid misuse and addiction," PhRMA president and CEO Stephen Ubl said.
Ubl continued, "It also allows scientists working on this issue to leverage lessons learned in other therapeutic areas across the research spectrum. The increased focus on public-private collaboration will allow us to better identify the most promising areas of research, apply lessons learned in other therapeutic areas and deliver new treatment options to patients faster."
Ubl went on to say, "America’s biopharmaceutical companies’ driving mission is to find new, innovative answers to our toughest health challenges, and we are committed to bringing that same determination to this urgent national crisis through the HPC and other ongoing industry efforts.”
The Pharmaceutical Research and Manufacturers of America together with the Advanced Medical Technology Association, the Biotechnology Innovation Organization, and the Foundation for the NIH, signed a memorandum of understanding with the NIH to become a part of the HPC to communicate opportunities to advance the goals of the initiative to its member companies and identify representatives with scientific expertise who may provide knowledge and guidance.
“Opioid abuse and addiction in America is a public health crisis that we all must work together to solve. The HEAL Partnership Committee is a critical step forward in this collaboration. It provides an opportunity to share valuable data, knowledge and research across the biopharmaceutical and medical device industries, government and academia to speed the development of innovative treatments for pain and opioid misuse and addiction," PhRMA president and CEO Stephen Ubl said.
Ubl continued, "It also allows scientists working on this issue to leverage lessons learned in other therapeutic areas across the research spectrum. The increased focus on public-private collaboration will allow us to better identify the most promising areas of research, apply lessons learned in other therapeutic areas and deliver new treatment options to patients faster."
Ubl went on to say, "America’s biopharmaceutical companies’ driving mission is to find new, innovative answers to our toughest health challenges, and we are committed to bringing that same determination to this urgent national crisis through the HPC and other ongoing industry efforts.”